Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.

Maojin You,Yufan Huang,Zhongjie Cai,Qingfeng Wu, Wei Zhu,Ying He,Ruijia Chen

Frontiers in oncology（2022）

引用 4|浏览1

暂无评分

摘要

From the Chinese healthcare system perspective, SIDCHM is considered a cost-effective treatment option compared with PLCHM as first-line therapy for advanced or metastatic ESCC.

查看译文

关键词

cost-effectiveness,esophageal squamous cell carcinoma,first-line treatment,placebo plus chemotherapy,sintilimab plus chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要